StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
TAH.NZ$5.00+4.17%
Fair $5.00+0.0%

TAH.NZ

Third Age Health Services Limited

Healthcare / Medical Care FacilitiesNZSE

$5.00

+0.20 (+4.17%)

Fairly Valued+0.0%Fair Value $5.00Fund rank 35/100 · Data gapFallback financials|
SA 57/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $2.5M · quality 71.3/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 80/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

57/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · TAH.NZLocal privado en este navegador · Third Age Health Services Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$50M

P/E

21.7x

↑

EV/EBITDA

11.3x

↓

ROE

60.9%

↑

Gross Margin

51.9%

↑

Debt/Equity

0.93

↑
52-Week Range$5
$3$7

TradingView lightweight chart

TAH.NZ price, volumen y niveles de valoración

Último $5.000Periodo +125.2%
Fair value: $5.000

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+47.9%

FCF CAGR

+49.6%

FCF margin

18.6%

FCF / Net income

1.52x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $19.1M · net income $2.3M · FCF $3.5M

2022-FY → 2025-FY

Gross margin

51.9%-10.7% pts

Operating margin

19.8%-6.5% pts

Net margin

12.3%-7.6% pts

FCF margin

18.6%+0.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$19.1M$19.1M$15.2M$11.2M$5.9M
Net Income$2.3M$2.3M$1.4M$438000.00$1.2M
EBITDA$4.5M$4.5M$3.0M$1.6M$1.7M
EPS——0.140.040.12
Gross Margin51.9%51.9%50.3%53.9%62.6%
Operating Margin19.8%19.8%14.8%8.7%26.3%
Net Margin12.3%12.3%9.1%3.9%19.9%
Balance Sheet
Debt/Equity0.930.931.422.090.40
Current Ratio1.051.05———
Cash Flow
Free Cash Flow$3.5M$3.5M$2.5M$1.0M$1.1M
Returns
ROE60.9%60.9%48.4%17.0%43.5%
Valuation
P/E21.7421.7412.4536.5323.31
EV/EBITDA11.3011.306.5712.8515.82
P/B12.9512.956.046.2210.14
Growth & Yield
Revenue Growth25.9%25.9%35.1%90.1%—
EPS Growth——215.3%-62.9%—
Dividend Yield3.3%3.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +57.2%

Total return

+57.2%

Start / end P/E

n/dx → n/dx

EPS bridge

0.14 → n/d

Residual

+53.8%

EPS growthn/d
Multiple reratingn/d
Dividend+3.3%
Residual / FX / buybacks / cross-term+53.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.